Tagomics, a UK-based developer of a platform for comprehensive disease insight and diagnosis, recently announced a successful funding round of £6.7M. The funding was led by Calculus Capital and saw participation from Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures, MEIF Proof of Concept & Early Stage Fund, Meltwind, and OMX Ventures. This financial boost follows a previous £1.6M pre-seed round led by IQ Capital and Start Codon, in addition to grant funding from Innovate UK. The company plans to utilize these funds to accelerate its scientific research and product development efforts, with a particular focus on enhancing cancer and other disease diagnosis and treatment methods.
Established in July 2020 as a spin-out from the University of Birmingham, Tagomics is spearheaded by CEO Dr.
Jack Kennefick. The company has designed a cutting-edge platform that integrates various "omics" technologies, such as genomics (to detect mutations), epigenomics (for studying chemical modifications on the genome), and fragmentomics (which involves analyzing DNA fragmentation patterns in the blood). By merging these methodologies and leveraging advanced data analysis techniques and machine learning algorithms, Tagomics aims to uncover novel cancer markers and forge strategic partnerships that advance drug development and therapy selection for patients.
In response to the funding news, Dr. Jack Kennefick emphasized the significance of Tagomics' multiomic approach in gaining a deeper understanding of diseases like cancer. By harnessing these insights, the company aims to develop more straightforward and precise methods for diagnosing and treating patients. Dr. Kennefick expressed his satisfaction in welcoming a diverse group of experienced investors on board, highlighting their role in driving the development of the platform and expanding the realm of genomic medicine capabilities.
Click here for a full list of 6,481+ startup investors in the UK